Journal
JOURNAL OF CLINICAL MICROBIOLOGY
Volume 58, Issue 7, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.01851-19
Keywords
adults; biomarkers; pediatrics; procalcitonin; sepsis
Categories
Funding
- Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health [K23 HD091365]
- National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23 DK119463]
Ask authors/readers for more resources
Sepsis is a complex process defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. It is associated with significant morbidity and mortality rates in both adults and children, and emphasis has been placed on its early recognition and prompt provision of antimicrobials. Owing to limitations of current diagnostic tests (i.e., poor sensitivity and delayed results), significant research has been conducted to identify sepsis biomarkers. Ideally, a biomarker could reliably and rapidly distinguish bacterial infection from other, noninfectious causes of systemic inflammatory illness. In doing so, a sepsis biomarker could be used for earlier identification of sepsis, risk stratification/prognostication, and/or guidance of antibiotic decision-making. In this minireview, we review one of the most common clinically used sepsis biomarkers, procalcitonin, and its roles in sepsis management in these three areas. We highlight key findings in the adult literature but focus the bulk of this review on pediatric sepsis. The challenges and limitations of procalcitonin measurement in sepsis are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available